NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that 15 posters have been accepted for presentation at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 12-15, 2010 in Boston, MA. The presentations include overviews on the unique properties of next-generation antibiotics delafloxacin and radezolid as well as the Company’s proprietary understanding of the bacterial ribosome which allows for the design and generation of novel antibiotics.
